CIK 0001534248 · Non-accelerated filer<br>Smaller reporting company
Chemomab Therapeutics Ltd.
Sign in to watch- Ticker
- CMMB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- EIN
- 813676773
- Phone
- 972-77-331-0156
- Business address
- KIRYAT ATIDIM, BUILDING 7, TEL AVIV, Israel
- Former names
- Anchiano Therapeutics Ltd., BioCancell Ltd.
- 8-K Event Results of operations
- DEF 14A Proxy Proxy Statement
- 424B5 Offering Prospectus
- 10-K Report Annual Report
- 4 Open-market buy Director bought 1,000 shares at an average $4.34 ($4,340)
- 4 Open-market buy Executive VP, CFO & COO bought 1,250 shares at an average $4.04 ($5,045)
- 4 Open-market buy Chief Executive Officer bought 2,500 shares at an average $3.98 ($9,943)
- 4 Open-market buy Director bought 6,000 shares at an average $4.35 ($26,120)
- 4 Open-market buy Director bought 1,200 shares at $4.28 ($5,136)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 8-K Event Results of operations
- 8-K Event Shareholder vote results
- SC 13G/A Stake Amended Statement of Ownership
- SC 13D Stake Beneficial Ownership Report
- DEF 14A Proxy Proxy Statement
- PRE 14A Proxy Proxy Statement (Preliminary)
Page 8 of 19 · 368 filings